C urrent guidelines recommend patients with acute coronary syndrome (ACS; unstable angina [UA], non-STsegment-elevation myocardial infarction [NSTEMI], or ST-segment-elevation myocardial infarction [STEMI]) and undergoing percutaneous coronary intervention (PCI) should receive a loading dose (LD) of a P2Y12 receptor inhibitor. [1] [2] [3] [4] Clopidogrel is the most broadly used P2Y12 receptor inhibitor and is often given upstream, administered en route to the hospital or in the emergency department, before knowing coronary anatomy. The antiplatelet effect of clopidogrel is variable, and patients with a reduced response have an increased risk of ischemic complications. [5] [6] [7] Prasugrel is a P2Y12 Background-Adding a prasugrel loading dose (LD) to a clopidogrel LD could be desirable because clopidogrel may fail to provide adequate levels of platelet inhibition in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Methods and Results-The pharmacodynamic response of prasugrel 60 mg LD alone was compared with prasugrel 60 mg or 30 mg added ≤24 hours to clopidogrel 600 mg in Transferring from Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients study-a multicenter, randomized, double-blind, double-dummy, 3-arm, parallel, active-comparator controlled study. Two hundred eighty-two patients were randomized to 3 LD strategies: placebo plus prasugrel 60 mg, clopidogrel 600 mg plus prasugrel 60 mg, or clopidogrel 600 mg plus prasugrel 30 mg. Platelet function was assessed using VerifyNow P2Y12 Reaction Units (PRU) immediately before prasugrel LD, and 2, 6, 24, and 72 hours after prasugrel LD in 149 patients with evaluable platelet function studies. At 6 hours after the prasugrel 60 mg LD, the least squares mean (95% confidence interval) difference between placebo/prasugrel 60 mg and clopidogrel 600 mg/prasugrel 60 mg (primary outcome) was 22.2 (−11.0 to 55.5; P=0.19; least squares mean PRU 57.9 versus 35.6, respectively). For clopidogrel 600 mg/prasugrel 30 mg (least squares mean PRU, 53.9), the difference was 3.9 (−28.2 to 36.1; P=0.81) versus placebo/prasugrel 60 mg. No significant differences in PRU were observed at any time point across the 3 groups. There were few bleeding events observed regardless of treatment. Conclusions-Platelet reactivity with prasugrel 60 mg LD added to clopidogrel 600 mg LD was not significantly different compared with prasugrel 60 mg LD alone in acute coronary syndrome patients undergoing percutaneous coronary intervention. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01115738.
receptor inhibitor that provides faster, higher, and more consistent platelet inhibition when compared with clopidogrel. [8] [9] [10] These pharmacodynamic (PD) properties may be important for ACS patients undergoing PCI, as demonstrated in a largescale clinical trial showing prasugrel to be more effective than clopidogrel in reducing subsequent ischemic events, although at a cost of increased bleeding events. 11 Therefore, in patients who have received a clopidogrel LD before PCI, addition of a prasugrel LD may be a desirable treatment option once the coronary anatomy is known and PCI is to be performed. Previous studies have examined the PD effect of switching from clopidogrel to prasugrel. [12] [13] [14] However, at the time of this study, none have described the effect of adding a prasugrel LD to a recently administered clopidogrel LD in real-world ACS patients undergoing PCI. The aim of the Transferring from Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET) study was to investigate the PD responses of 3 LD strategies involving prasugrel in addition to clopidogrel or placebo in ACS patients undergoing planned PCI.
Methods

Patient Population and Study Design
The TRIPLET study was a randomized, double-blind, double-dummy, 3-arm, parallel, active-comparator controlled study performed at 36 sites in 8 countries (see online-only Data Supplement). This study was designed to evaluate the PD response in ACS patients who are likely to undergo PCI using 3 different strategies: placebo plus prasugrel 60 mg LD, clopidogrel 600 mg LD plus prasugrel 60 mg LD, or clopidogrel 600 mg LD plus prasugrel 30 mg LD. Patients were eligible for the study if they were hospitalized with ACS (UA/NSTEMI or STEMI) and anticipated to undergo PCI <24 hours of the placebo/clopidogrel LD, weighed ≥60 kg, and were ≥18 years of age but <75 years of age. Patients were excluded if they had a high risk of bleeding or a previous history of transient ischemic attack or stroke. See online-only Data Supplement for a full description of inclusion and exclusion criteria. All patients were treated with aspirin with dosing at the discretion of the investigator. The planned use of intravenous glycoprotein IIb/IIIa inhibitors was not allowed because their use would interfere with the PD measurements although the unplanned use of these agents as clinically indicated was permitted.
After screening and completion of informed consent, eligible ACS patients who were to undergo PCI were randomly assigned in a 1:1:1 ratio by an interactive voice response system to receive 1 of the 3 LD strategies as defined above. The first LD (placebo or clopidogrel 600 mg) was administered ≤24 hours before PCI and the second LD (prasugrel 30 or 60 mg) was administered once the decision was made to perform PCI (Figure 1 ). Patients not undergoing PCI did not receive the second LD, as prasugrel is only indicated in ACS patients managed with PCI. Twenty-four hours after prasugrel LD, patients were given prasugrel 10 mg maintenance dose once daily for a minimum of 2 and a maximum of 4 days. At the end of the study, commercial clopidogrel or prasugrel was continued at the discretion of the investigator.
Platelet function was tested at 5 time points during the study: after the first LD (placebo or clopidogrel) immediately before the second (prasugrel) LD (baseline), and at 2±1, 6±1, 24±4, and 72±24 hours after prasugrel LD. The protocol recommended that in UA/NSTEMI patients the baseline blood sample for platelet function measurements be collected ≥6 hours after the placebo/clopidogrel LD to provide enough time to achieve the maximum level of platelet inhibition by clopidogrel. 15 For STEMI patients, the baseline blood sample was collected immediately before prasugrel LD anytime after the placebo/clopidogrel LD. Platelet function was assessed using P2Y12 Reaction Units (PRU) determined by the point-of-care VerifyNow (VN) P2Y12 assay (Accumetrics Corporation, San Diego, CA) according to standard protocols. 16 Device-reported percent inhibition of platelet aggregation was computed by the VN device.
Institutional review boards at the individual sites approved the protocol, and all patients provided written informed consent. The study was conducted in accordance with regulatory standards and good clinical practice guidelines.
Study End Points and Statistical Analysis
Our primary hypothesis was that prasugrel 60 mg LD alone provides a similar level of platelet inhibition as clopidogrel 600 mg LD plus an additional prasugrel 60 mg LD. The primary analysis population was the PD population, which included all randomized patients who received both the first (placebo/clopidogrel) and second (prasugrel) LD and had ≥1 evaluable PD measurement at any time point after the second LD. All PD analyses were confined to evaluable PD measurements, defined as samples: (1) from patients who did not have a protocol violation that would interfere with the VN assay, (2) from patients who did not receive glycoprotein IIb/IIIa inhibitors before PD sampling, (3) drawn within the prespecified windows as defined
WhAT IS KNOWN
• Patients with acute coronary syndrome and planned for percutaneous coronary intervention are often administered a loading dose of clopidogrel before reaching the cardiac catheterization laboratory, but based on the results of TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction (TRITON-TIMI 38), interventional cardiologists may prefer that these patients be treated with prasugrel.
• Pharmacodynamic data for transitioning directly from a clopidogrel loading dose to a prasugrel loading dose were not available.
WhAT ThE STuDy ADDS
• This study shows that administering a prasugrel loading dose ≤24 hours of a clopidogrel loading dose resulted in platelet reactivity (as measured by VerifyNow P2Y12 Reaction Units) that was not different compared with that with a prasugrel loading dose alone. above, and (4) assay run within 10 minutes to 4 hours after blood sample collection.
The primary end point for this study was the VN-reported PRU, measured 6 hours after prasugrel LD. The primary analysis compared the mean difference in VN-reported PRU between patients receiving placebo/prasugrel 60 mg LD and those receiving clopidogrel 600 mg/prasugrel 60 mg LD. A linear mixed model for repeated measures, assuming unstructured covariance, was used to calculate least squares (LS) mean estimates at 6 hours after prasugrel LD with all evaluable PRU values. Treatment, country, visit, and treatmentby-visit interaction terms were included as fixed effects, and patient and error as random effects. The same model was used to compare the placebo LD/prasugrel 60 mg LD group with the clopidogrel 600 mg/prasugrel 60 mg and clopidogrel 600 mg/prasugrel 30 mg groups at all collected time points (2, 6, 24, and 72 hours after prasugrel LD) and applied to all evaluable PD measurements. The LS means were estimated for each treatment group, including the pairwise differences between the placebo/prasugrel 60 mg treatments with 95% confidence intervals (CIs). Additionally, P values testing the difference at each time point were completed. This analysis approach was repeated for device-reported percent inhibition at all time points. Exploratory analyses of high-risk subgroups (ACS diagnosis, diabetes mellitus, sex, and age) were conducted by extending the primary mixed model for repeated measures by subgroup and subgroupby-treatment terms. SAS (version 9.2; SAS Institute, Cary, NC) was used for all statistical analyses.
At the time of protocol development, there was no consensus on a clinically important difference in PRU or device-reported percent inhibition, which precluded definition of a relevant noninferiority margin and the use of a noninferiority design. The SD was initially based on previous prasugrel PD studies, and during the study, further PD data regarding the underlying statistical assumptions and expected SD became available. 14, 17 Based on this, the final sample size of 31 patients per treatment group with evaluable PD was determined using a SD of 20 and a 2-sided precision of 10 for the difference in means. As the initial study dose occurred before coronary angiography, a large number of patients did not undergo PCI. Additionally, there were several patients who did not have an evaluable PD sample. An assessment committee blinded to actual platelet function results was assembled to ensure each arm would have ≥31 patients with evaluable PD at the conclusion of enrollment. Based upon their findings, randomization into clopidogrel 600 mg/prasugrel 60 mg was discontinued for the last 2 months of the 18-month study enrollment period while maintaining the double-blind study design. The results reflect the patient population at the termination of enrollment.
Safety data were summarized for all reports of bleeding, adverse events, vital signs, and laboratory parameters. Treatment-emergent adverse events (TEAEs) were summarized using the Medical Dictionary for Regulatory Activities (MedDRA; version 14.1)preferred term. The safety population consisted of all randomized patients who received any dose of study drug (placebo, clopidogrel, or prasugrel).
Results
Patient Population
From May 2010 through November 2011, 287 patients were screened and 282 patients were randomized. The safety population included 276 patients analyzed according to treatment assignment, all of which, except for 3, underwent diagnostic angiography. The PD population (N=149 patients) was equally distributed across the 3 treatment arms. Ninety-eight percent of the PD population underwent PCI, with 1 patient from each group included in the primary analysis who received a LD of prasugrel but did not undergo PCI (Figure 2 ). Demographics and baseline characteristics were not significantly different across the 3 treatment groups in both the safety (Table) and PD populations (online-only Data Supplement Table I ).
PD Results
At 6 hours after prasugrel LD, there was no significant difference between the LS mean PRU for the primary end point (placebo/prasugrel 60 mg versus clopidogrel 600 mg/prasugrel 60 mg, 57.9 versus 35.6; LS mean difference [95% CI], 22.2 [−11.0 to 55.5]; P=0.19); nor for placebo/prasugrel 60 mg versus clopidogrel 600 mg/prasugrel 30 mg (LS mean PRU, 53.9; 3.9 [−28.2 to 36.1]; P=0.81; Figure 3A ; online-only Data Supplement Table II ). Consistent with the PRU results, there was no significant difference in LS mean in percent inhibition at 6 hours across the 3 treatment groups ( Figure 3B ).
No differences in LS mean PRU were observed at any time point when comparing the placebo/prasugrel 60 mg group with the clopidogrel 600 mg/prasugrel 60 mg and clopidogrel . PD population consisted of all randomized patients who received the prasugrel LD and had an evaluable PD measurement after prasugrel loading dose. LD indicates loading dose; and PD, pharmacodynamic. *Patients with evaluable measurements did not have a protocol violation that would interfere with the VerifyNow P2Y12 assay, did not receive glycoprotein IIb/IIIa inhibitors before PD sampling, had their blood sample for measurement drawn within prespecified window, had assay run in specified window, and had VerifyNow P2Y12 BASE value >200. 600 mg/prasugrel 30 mg groups ( Figure 4A ). Median PRU values at all time points across the 3 treatment groups were similar (online-only Data Supplement Figure I ).
There were no significant differences in LS mean percent inhibition found for the comparison of placebo/prasugrel 60 mg with clopidogrel 600 mg/prasugrel 30 mg at any time point ( Figure 4B) . When comparing the placebo/prasugrel 60 mg with clopidogrel 600 mg/prasugrel 60 mg, there was no significant difference in LS mean percentage inhibition except at the 24-hour time point (−10.1 [−20.1 to −0.04]; P=0.05). 
Baseline Response (Safety Population)
Baseline PRU showed a relatively modest response to clopidogrel LD compared with placebo. A post hoc analysis, including time between the LD as terms, compared the placebo group with the pooled clopidogrel LD groups; the difference (SE) of 27.7 (17. 3) between PRUs (SE), 266.7 (14.2) versus 239.1 (10.5), respectively, was not statistically significant (P=0.11).
The median time in the study between placebo/clopidogrel LD and prasugrel LD for the overall population was 2.0 hours. However, a bimodal distribution of timing between LDs (online-only Data Supplement Figure II) was observed. In the majority of patients (n=116), there was ≤6 hours between the LDs (median time between LDs, 1.2 hours), and in the remainder of patients (n=29), >12 hours between their LDs (median time, 19.6 hours). When the PD assay was collected 0 to ≤6 hours between LDs, there was little difference in PRU at baseline whether they received clopidogrel or placebo as the first LD (online-only Data Supplement Table IV ). However, the PRU at baseline in the group treated >6 hours between LD was not significantly different from that in the group treated ≤6 hours between LDs.
Safety and Tolerability
In the safety population (n=276), TEAEs were evenly distributed across treatment groups. There were 14 hemorrhagic TEAEs in 12 patients (3 in the placebo LD/prasugrel 60 mg group; 4 in the clopidogrel 600 mg LD/prasugrel 60 mg LD group; and 7 in the clopidogrel 600 mg LD/prasugrel 30 mg LD group; online-only Data Supplement Table V ). Six were determined by the investigator to be related to study drug (2 in each group). Three were serious bleeding events in 2 patients (both in clopidogrel 600 mg/prasugrel 60 mg treatment group), 1 of which was related to study drug. Two patients experienced a hemoglobin change from baseline (decrease of >3 g/dL); however, neither of these patients received prasugrel LD as both did not proceed to PCI.
There were 2 deaths in the placebo/prasugrel 60 mg LD treatment group (cardiorespiratory arrest and cardiogenic shock). Neither was reported as being related to study drug or study procedure, nor was hemorrhagic in nature.
Discussion
The TRIPLET study evaluated the pharmacodynamics of administering prasugrel LD after clopidogrel LD. The study found that there was no statistical difference in the PRU observed after prasugrel 60 mg LD in addition to clopidogrel 600 mg LD, when compared with prasugrel 60 mg LD alone. Additionally, when prasugrel 30 mg LD was added to clopidogrel LD, the results were not significantly different from when 60 mg was used. Although a difference of 22 PRU was noted between the placebo/prasugrel 60 mg group and the clopidogrel 600 mg/prasugrel 60 mg cohorts, it is unlikely that this difference would result in a differential clinical effect, particularly at the low levels of PRU observed in this study. This is supported by a recent study in which a PRU change of 60 units was not correlated with a difference in clinical outcome. 18 In TRIPLET, when examining results in key subgroups, PRU results across time were consistent with that of the overall study with the exception of the STEMI subgroup. In this subgroup, at 2 hours after prasugrel LD, there was numerically less response to prasugrel 30 mg when added to clopidogrel 600 mg compared with prasugrel 60 mg added to either clopidogrel 600 mg or the placebo group. By 6 hours, the difference in PRU, regardless of treatment group, was negligible. A delayed response in the STEMI patients treated with prasugrel 30 mg may be related to greater platelet reactivity observed in STEMI patients. 19 However, because of the small sample size, comparisons between prasugrel LDs in the STEMI subgroup should be treated with caution. Previously, in patients with stable coronary artery disease on prasugrel 10 mg maintenance dose, the decrease in PRU to prasugrel 30 mg was slightly, but significantly, less than to prasugrel 60 mg at 4 hours after the LD. 20 In the present study, no notable differences were seen at any time point among the 3 LD strategies in patients with UA/NSTEMI.
In TRIPLET, it is noteworthy that in the first 4 hours after clopidogrel 600 mg LD, there was little apparent response in most patients. Even after 6 or 12 hours, the response to clopidogrel was less than the response to either prasugrel LD. These findings are consistent with other reports showing that even after several hours of clopidogrel treatment, platelet reactivity may be only modestly reduced, including in ACS patients. 21, 22 High platelet reactivity in the early phases of clinical presentation is associated with an increased risk of ischemic complications in ACS patients. 6 This underscores the need for more optimal platelet-inhibiting strategies.
There was also significant degree of variability observed in PRU measurements after placebo or clopidogrel 600 mg at baseline. Factors that may have influenced these results include a well-documented variable and modest response to clopidogrel, 5 which seems to be further attenuated in patients with ACS. 23, 24 Additionally, the relatively short time window between clopidogrel LD and baseline platelet function measurement may not have allowed for an adequate response to clopidogrel. 16, 25 Although in the majority of patients the time between the 2 LDs was <6 hours (reflective of contemporary practice in centers participating in this study), the level of PRU was still relatively high in the group of patients who had clopidogrel given >12 hours before prasugrel.
Treatment with prasugrel LD alone almost completely saturates the P2Y 12 receptor. 26 Therefore, addition of prasugrel to clopidogrel LD would only allow the active metabolite of prasugrel to bind to receptors not already occupied by the active metabolite of clopidogrel. This should produce little difference in platelet function and, therefore, bleeding risk compared with administering prasugrel alone. To date, there is controversy as to whether a PRU threshold exists for bleeding. In fact, some studies have shown an association between PRU and bleeding, albeit with different thresholds identified, 27, 28 although this was not shown in others. 29, 30 At the level of PRU observed in the placebo/prasugrel 60 mg arm, it is uncertain whether the nonsignificant difference in PRU by adding prasugrel LD on top of clopidogrel LD would confer additional bleeding risk. Additionally, the effect on PRU using this strategy should only be apparent only during the periprocedural period, where a high level of platelet inhibition is desirable. There should be no effect of this combination of agents during the maintenance phase of therapy, which would reflect the effect of prasugrel 10 mg maintenance dose. In TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction (TRITON-TIMI 38), there was no significant difference in bleeding between prasugrel and clopidogrel during the LD (periprocedural) phase, despite a large difference in platelet inhibition between the 2 drugs, while most of the difference in bleeding occurred during the maintenance dose phase. 31 Although this trial was too small to evaluate bleeding definitively, there was no signal suggesting increased bleeding when prasugrel 60 mg was added to clopidogrel 600 mg compared with that of prasugrel 60 mg alone. Additionally, no previously unreported or clinically relevant TEAEs were noted, and nonhemorrhagic TEAEs were evenly distributed across the treatment groups. 11, 32 Ultimately, in view of the small, nonsignificant difference between the prasugrel 60 mg and prasugrel 30 mg LD groups, lack of a bleeding signal, and observed modest response in STEMI patients at 2 hours to prasugrel 30 mg, this study suggests that prasugrel 60 mg should be the preferred LD in ACS patients undergoing PCI, regardless of whether the patient has been pretreated with clopidogrel.
Study Limitations
Not all patients randomized in this study proceeded to PCI, as enrollment and administration of the first LD of study drug was before diagnostic angiography and determination of patient suitability for PCI. This limited the number of patients receiving prasugrel LD because prasugrel was given only to ACS patients undergoing PCI. This level of dropout has been seen in other PD studies performed in ACS patients in a realworld setting. 13, 33, 34 Such reduced number of patients in the PD population and the higher-than-expected variability reduced the precision of the difference estimates between treatments.
Conclusions
Many ACS patients continue to be loaded with clopidogrel before knowing coronary anatomy. In clinical practice, there may not be time to perform platelet function testing before PCI in an attempt to guide therapy after clopidogrel LD, nor is there consensus on how to alter therapeutics based on PD results. This study found that the PD effect of adding prasugrel 60 mg LD after clopidogrel 600 mg LD within the previous 24 hours was not significantly different compared with prasugrel 60 mg LD alone, and the response was consistent across important clinical subgroups. Although not powered to detect clinical safety or efficacy differences between the treatment groups, there were few bleeding events observed regardless of treatment group. TRIPLET provides a more comprehensive understanding of the effects of combining clopidogrel and prasugrel LDs on platelet inhibition, as well as insights and potential guidance to physicians regarding the expected PD effect of initiation of prasugrel in ACS patients already loaded with clopidogrel. Further studies are warranted to elucidate the clinical implications of these PD findings.
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